Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.
paper
Cited
Public
Unavailable
- Authors
- Stopponi, Serena; de Guglielmo, Giordano; Somaini, Lorenzo; Cippitelli, Andrea; Cannella, Nazzareno; Kallupi, Marsida; Ubaldi, Massimo; Heilig, Markus; Demopulos, Gregory; Gaitanaris, George; Ciccocioppo, Roberto
- Year
- 2013
- Journal
- Alcoholism, clinical and experimental research
- PMID
- 23550625
- DOI
- 10.1111/acer.12091
BACKGROUND: Pioglitazone is a selective peroxisome proliferator-activated receptor γ (PPARγ) agonist used for the treatment of insulin resistance and type 2 diabetes. Previous studies conducted in our laboratory showed that activation of PPARγ by pioglitazone reduces alcohol drinking, stress-induced relapse, and alcohol withdrawal syndrome in rats. Pioglitazone was not able to prevent relapse elicited by alcohol cues. Conversely, the nonselective opioid antagonist naltrexone has been shown to reduce alcohol drinking and cue- but not stress-induced relapse in rodents. METHODS: Based on these findings, this study was sought to determine the efficacy of pioglitazone and naltrexone combination on alcohol intake and relapse behavior. Genetically selected alcohol-preferring Marchigian Sardinian (msP) rats were used for the study. RESULTS: Pioglitazone (10 and 30 mg/kg) and naltrexone (0.25 and 1.0 mg/kg) each individually reduced alcohol drinking in msP rats. The combination of the 2 drugs resulted in a more potent alcohol drinking reduction than single agents. Confirming previous studies, pioglitazone (10 and 30 mg/kg) significantly reduced relapse induced by the pharmacological stressor yohimbine (1.25 mg/kg) but not by cues predictive of alcohol availability. Conversely, naltrexone reduced reinstatement of drug seeking elicited by alcohol cues but not by yohimbine. CONCLUSIONS: The drug combination was effective in reducing both relapse behaviors. These findings open new vistas in the use pioglitazone in combination with naltrexone for the treatment of alcoholism.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Cannabinoid-based Pharmacology for the Management of Substance Use Disorders. | Luján MÁ et al. | — | 2026 | → |
| Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT<sub>1A</sub> receptor mechanism: Exploration of other potential receptor targets. | Badolato CJ et al. | — | 2025 | → |
| A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder. | Mason BJ et al. | — | 2024 | → |
| Neuroimmune modulators as novel pharmacotherapies for substance use disorders. | Grodin EN | — | 2024 | → |
| Novel medications for problematic alcohol use. | Heilig M et al. | — | 2024 | → |
| A review on the reciprocal interactions between neuroinflammatory processes and substance use and misuse, with a focus on alcohol misuse. | Gano A et al. | — | 2023 | → |
| DDS Perspective: Time to Get Serious About the Global Pandemic. | Carr RM | — | 2022 | → |
| Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats. | Alhaddad H et al. | — | 2022 | → |
| Functional interactions between cannabinoids, omega-3 fatty acids, and peroxisome proliferator-activated receptors: Implications for mental health pharmacotherapies. | Jung T et al. | — | 2022 | → |
| Rewarding effect of ethanol-induced conditioned place preference in mice: Effect of the monoterpenoid linalool. | Yunusoğlu O | — | 2022 | → |
| Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions. | Khera R et al. | — | 2022 | → |
| Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies. | Curley DE et al. | — | 2022 | → |
| Activation of peroxisome proliferator-activated receptor γ reduces alcohol drinking and seeking by modulating multiple mesocorticolimbic regions in rats. | Fotio Y et al. | — | 2021 | → |
| Andrographis paniculata and Its Main Bioactive Ingredient Andrographolide Decrease Alcohol Drinking and Seeking in Rats Through Activation of Nuclear PPARγ Pathway. | Stopponi S et al. | — | 2021 | → |
| Genetically selected alcohol-preferring msP rats to study alcohol use disorder: Anything lost in translation? | Borruto AM et al. | — | 2021 | → |
| Immune treatments for alcohol use disorder: A translational framework. | Meredith LR et al. | — | 2021 | → |
| N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats. | Fotio Y et al. | — | 2021 | → |
| PGC-1α Signaling Increases GABA(A) Receptor Subunit α2 Expression, GABAergic Neurotransmission and Anxiety-Like Behavior in Mice. | Vanaveski T et al. | — | 2021 | → |
| Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. | Sagheddu C et al. | — | 2021 | → |
| Argan oil supplementation attenuates voluntary ethanol consumption and withdrawal syndrome promoted by adolescent intermittent ethanol in rat. | El Mostafi H et al. | — | 2020 | → |
| Further evidence for the involvement of the PPARγ system on alcohol intake and sensitivity in rodents. | Domi E et al. | — | 2020 | → |
| Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19. | Niu W et al. | — | 2020 | → |
| Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects. | Brunetti P et al. | — | 2020 | → |
| Potential of Glial Cell Modulators in the Management of Substance Use Disorders. | Jones JD | — | 2020 | → |
| Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. | Matheson J et al. | — | 2020 | → |
| Toll-Like Receptor 4 Signaling and Drug Addiction. | Wu R et al. | — | 2020 | → |
| Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission. | Domi E et al. | — | 2019 | → |
| Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. | Yammine L et al. | — | 2019 | → |
| Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders. | Melbourne JK et al. | — | 2019 | → |
| Kappa opioid receptors mediate yohimbine-induced increases in impulsivity in the 5-choice serial reaction time task. | Funk D et al. | — | 2019 | → |
| Neuroimmune signaling in alcohol use disorder. | Erickson EK et al. | — | 2019 | → |
| Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies. | Kohno M et al. | — | 2019 | → |
| Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework. | Greenwald MK | — | 2018 | → |
| Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. | Schroeder JR et al. | — | 2018 | → |
| Ethanol and Cytokines in the Central Nervous System. | Roberto M et al. | — | 2018 | → |
| Inhibition of fatty acid amide hydrolase in the central amygdala alleviates co-morbid expression of innate anxiety and excessive alcohol intake. | Stopponi S et al. | — | 2018 | → |
| Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver. | Ferguson LB et al. | — | 2018 | → |
| PPARγ agonism attenuates cocaine cue reactivity. | Miller WR et al. | — | 2018 | → |
| The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. | Jones JD et al. | — | 2018 | → |
| Transcriptional Regulators as Targets for Alcohol Pharmacotherapies. | Savarese AM et al. | — | 2018 | → |
| An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders. | Barajaz AM et al. | — | 2017 | → |
| Genetic studies of alcohol dependence in the context of the addiction cycle. | Reilly MT et al. | — | 2017 | → |
| Glial and neuroinflammatory targets for treating substance use disorders. | Bachtell RK et al. | — | 2017 | → |
| Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain. | Cosa A et al. | — | 2017 | → |
| Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. | Jones JD et al. | — | 2017 | → |
| PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. | Schmitz JM et al. | — | 2017 | → |
| Protection against alcohol-induced neuronal and cognitive damage by the PPARγ receptor agonist pioglitazone. | Cippitelli A et al. | — | 2017 | → |
| Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. | Ubaldi M et al. | — | 2016 | → |
| Genetic Deletion of Neuronal PPARγ Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPARγ Function. | Domi E et al. | — | 2016 | → |
| Inflammatory responses to alcohol in the CNS: nuclear receptors as potential therapeutics for alcohol-induced neuropathologies. | Kane CJ et al. | — | 2016 | → |
| Localization of PPAR isotypes in the adult mouse and human brain. | Warden A et al. | — | 2016 | → |
| PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice. | Blednov YA et al. | — | 2016 | → |
| Preclinical Medication Development: New Targets and New Drugs. | Kasten CR et al. | — | 2016 | → |
| Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. | Mantsch JR et al. | — | 2016 | → |
| The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. | Jones JD et al. | — | 2016 | → |
| Investigational therapies for the pharmacological treatment of alcoholism. | Hillemacher T et al. | — | 2015 | → |
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | — | 2015 | → |
| PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission. | de Guglielmo G et al. | — | 2015 | → |
| Analgesic tolerance to morphine is regulated by PPARγ. | de Guglielmo G et al. | — | 2014 | → |
| Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date. | Lee MR et al. | — | 2014 | → |
| Endogenous opiates and behavior: 2013. | Bodnar RJ | — | 2014 | → |
| Fetal alcohol spectrum disorders and neuroimmune changes. | Drew PD et al. | — | 2014 | → |
| Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. | Robinson G et al. | — | 2014 | → |
| PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. | Ferguson LB et al. | — | 2014 | → |
| Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. | Le Foll B et al. | — | 2013 | → |